fda compounding semaglutide crackdown october 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our FDA restricts non-approved compounded GLP-1

Intramuscular injection causes semaglutide to absorb much faster than intended, which can increase side effects like bloating , dizziness , and fatigue while potentially reducing the duration of the medication effect between doses

Frequently Asked Questions Can natural foods increase GLP-1 levels as effectively as medications

ONdrugDelivery, Issue 160 (May 2024) , pp 4246

-1 (GLP-1RA) T2MD

At the American Diabetes Association (ADA) 2025 conference: Eli Lilly presented bimagrumab plus semaglutide for improved muscle retention

Read full article Introduction Many patients beginning GLP 1 medications such as Semaglutide or Tirzepatide want clear expectations about how quickly results will appear